Gilead Sciences’ Promising Phase 3 Study on Triple Negative Breast Cancer

Gilead Sciences ((GILD)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study.

Gilead Sciences is conducting a Phase 3 clinical study titled ‘A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy.’ The study aims to evaluate the effectiveness and safety of sacituzumab govitecan-hziy combined with pembrolizumab compared to the treatment of physician’s choice in patients with triple-negative breast cancer post-surgery.

The study is testing the combination of sacituzumab govitecan-hziy and pembrolizumab, both administered intravenously, against standard treatments involving pembrolizumab alone or with capecitabine. The goal is to determine if the experimental combination offers better outcomes for patients.

This interventional study is randomized with a parallel assignment model and no masking. Its primary purpose is treatment-focused, aiming to provide insights into more effective post-surgical therapies for this aggressive cancer type.

The study began on December 12, 2022, and is currently recruiting participants. The primary completion date is anticipated to be in 2025, with the last update submitted on June 24, 2025. These dates are crucial for tracking the study’s progress and potential data release.

The outcome of this study could significantly impact Gilead Sciences’ stock performance, as positive results may enhance their market position in oncology. Investors should watch for updates, as successful trials could shift market dynamics, especially in the competitive landscape of cancer treatment.

The study is ongoing, and further details can be accessed on the ClinicalTrials portal.